Impact of nasal continuous positive airway pressure treatment on quality of life in patients with obstructive sleep apnoea

Obstructive sleep apnea screening, diagnosis, and treatment in the transportation industry

Obstructive sleep apnea (OSA) is a common, identifiable, and treatable disorder with serious health, safety, and financial implications-including sleepiness- related crashes and incidents-in workers who perform safety-sensitive functions in the transportation industry. Up to one-third of crashes of large trucks are attributable to sleepiness, and large truck crashes result in more than 4,000 deaths annually. For each occupant of a truck who is killed, 6 to 7 occupants of other vehicles are killed. Treatment of OSA is cost-effective, lowers crash rates, and improves health and well-being. A large body of scientific evidence and expert consensus supports the identification and treatment of OSA in transportation operators. An Advanced Notice of Proposed Rulemaking regarding the diagnosis and treatment of OSA in commercial truck and rail operators was issued by the Federal Motor Carrier Safety Administration and Federal Railroad Administration, but it was later withdrawn. This reversal of the agencies' position has caused confusion among some, who have questioned whether efforts to identify and treat the disorder are warranted. In response, we urge key stakeholders, including employers, operators, legislators, payers, clinicians, and patients, to engage in a collaborative, patient-centered approach to address the disorder. At a minimum, stakeholders should follow the guidelines issued by a medical review board commissioned by the Federal Motor Carrier Safety Administration in 2016 alone, or in combination with the 2006 criteria, "Sleep Apnea and Commercial Motor Vehicle Operators," a Statement from the Joint Task Force of the American College of Chest Physicians, the American College of Occupational and Environmental Medicine, and the National Sleep Foundation developed by a joint task force. As research in this area continues to evolve, waiting is no longer an option, and the current standard of care demands action to mitigate the burden of serious health and safety risks due to this common, treatable disorder.

CITATION

Das AM, Chang JL, Berneking M, Hartenbaum NP, Rosekind M, Gurubhagavatula I. Obstructive sleep apnea screening, diagnosis, and treatment in the transportation industry. J Clin Sleep Med. 2022;18(10):2471-2479.

[Effects of continuous positive airway pressure on depression, anxiety and quality of life in obstructive sleep apnea hypopnea syndrome patients]

INTRODUCTION

The obstructive sleep apnea hypopnea syndrome (OSAHS) is a chronic stressor that may alter the emotional state and quality of life (QOL) of patients suffering from it. In this work, we proposed to estimate the prevalence of depression and anxiety, to assess the QOL in a Tunisian population of apneic patients, and to assess their evolution under continuous positive airway pressure (CPAP).

METHODS

We conducted a prospective study, involving 33 apneic patients followed for SAHOS with moderate or severe class disease in the pneumology department at Hedi Chaker university hospital in Sfax, Tunisia. They received CPAP treatment for three months. We used an epidemiological record. Two scales, the Hospital Anxiety and Depression Scale (HADS) and the 36-item Short-Form Health Survey (SF-36), were completed before and after treatment to evaluate the effect of three months of treatment with CPAP.

RESULTS

The prevalence of depression in the study's patients, according to the HADS, was 45.5% and that of anxiety was 21.2%. After 3months of CPAP, the prevalence of depression and anxiety had become 18.2% and 6.1%, respectively. QOL was impaired in 81.8% of cases before treatment, according to the SF-36. This figure had decreased to 69.7% after 3months of treatment with CPAP. Apart from the third dimension (physical pain), all other dimensions were significantly improved after 3months of CPAP treatment. The treatment with CPAP induced a significant improvement in the average scores of depression (P<0.001), anxiety (P=0.002) and QOL (P<0.001).

CONCLUSIONS

These results attest to the importance of the frequency of anxio-depressive disorders as well as an altered QOL in patients with OSAHS. CPAP treatment was shown to be effective in improving these parameters, but this efficacy was partial. Specialized care may be needed in cases of residual anxio-depressive symptoms.

Sleepiness and Driving: Benefits of Treatment

Drowsy driving is common and causes 21% of fatal crashes. Individuals at risk include young men, shift workers, older adults, and people with chronic short sleep duration, untreated obstructive sleep apnea (OSA), and narcolepsy. Untreated OSA is a particular concern in commercial drivers, who are at higher risk for the disorder. Treatment for sleep problems such as sleep extension for chronic short sleep, positive airway pressure (PAP) for OSA, pharmacologic treatments, and drowsy driving countermeasures may reduce the risk of crashes. Implementing screening measures to identify common sleep problems contributing to drowsy driving continues to be of high importance.

Sleep-disordered breathing and self-reported general health status in Thai patients

Background: Sleep-disordered breathing (SDB) has been a rapidly increasing health problem in Thai. Its effect on quality of life of Thai patients has not been adequately addressed. Objective: Determine the relationship between SDB and self-reported general health status in Thai patients. Materials and methods: A descriptive and cross-sectional study was used. Two hundred and sixtyeight patients (195 men and 73 women, age: 16-82 years) are recruited from King Chulalongkorn Memorial Hospital between January 2006 and December 2007. A health profile was obtained by self-administered questionnaire. SDB severity was assessed using an attended single-night comprehensive polysomnography. Results: SDB was not directly associated with the general health status. Presence of excessive daytime sleepiness, which was the major symptom of obstructive sleep apnea, was associated with a decrease in all domains of Short Form 36. Age, sex, and body mass index were also related to a lower physical function. Hypertension and excessive daytime sleepiness were associated with the severity of SDB. Conclusion: SDB is indirectly related to a lower general health status, and this relationship is of clinical significance.

Management of Obstructive Sleep Apnea in Commercial Motor Vehicle Operators: Recommendations of the AASM Sleep and Transportation Safety Awareness Task Force

ABSTRACT

The American Academy of Sleep Medicine Sleep and Transportation Safety Awareness Task Force responded to the Federal Motor Carrier Safety Administration and Federal Railroad Administration Advance Notice of Proposed Rulemaking and request for public comments regarding the evaluation of safety-sensitive personnel for moderate-to-severe obstructive sleep apnea (OSA). The following document represents this response. The most salient points provided in our comments are that (1) moderate-to-severe OSA is common among commercial motor vehicle operators (CMVOs) and contributes to an increased risk of crashes; (2) objective screening methods are available and preferred for identifying at-risk drivers, with the most commonly used indicator being body mass index; (3) treatment in the form of continuous positive airway pressure (CPAP) is effective and reduces crashes; (4) CPAP is economically viable; (5) guidelines are available to assist medical examiners in determining whether CMVOs with moderate-to-severe OSA should continue to work without restrictions, with conditional certification, or be disqualified from operating commercial motor vehicles.

Quality of life in patients with obstructive sleep apnea: Relationship with daytime sleepiness, sleep quality, depression, and apnea severity

The aim of this study was to investigate the relative contributions of daytime sleepiness, sleep quality, depression, and apnea severity to mental and physical quality of life (QoL) in obstructive sleep apnea (OSA) patients. This was a cross-sectional study. Participants were adults diagnosed with OSA. Medical Outcomes Study-Short Form 36 (SF-36), Epworth Sleepiness Scale (ESS), Medical Outcomes Study-Sleep Scale, and Beck Depression Inventory (BDI) were used. The factors predicting the physical and mental QoL were evaluated using multiple linear regression analysis. Seven hundred ninety three OSA patients participated in the study. The average age was 48.9 years (SD = 11.7 years). The mean apnea-hypopnea index (AHI) was 29.5 hour(-1) (SD = 20.6 hour(-1)). The SF-36 scores were 72.6 (SD = 18.5). The BDI, sleep quality, and age were related to both mental and physical QoL. However, ESS, minimal arterial oxygen saturation, gender, and body mass index were associated with the physical but not mental QoL. The BDI was the strongest predictor of both physical and mental QoL. AHI was related to neither physical nor mental QoL. The potential factors affecting QoL are different between physical and mental dimensions of QoL. Depressive mood was the strongest predictor of both the physical and mental QoL.

The management of surgical patients with obstructive sleep apnea

Obstructive sleep apnea (OSA) is a leading public health problem in both developed and developing nations. However, awareness regarding diagnostic options, management, and consequences of untreated OSA remains inadequate in the perioperative period. Adverse surgical outcomes appear to be more frequent in OSA patients. Immediate postoperative complications may be partially attributed to the negative effects of sedative, analgesic, and anesthetic agents that can worsen OSA by decreasing pharyngeal tone and the arousal responses to hypoxia, hypercarbia, and obstruction. Rebound rapid eye movement sleep after anesthesia and the use of opioids may contribute to adverse events in the postoperative period. Even though data to guide clinicians in the perioperative period is scarce, heightened awareness is recommended.

Obstructive sleep apnea syndrome: natural history, diagnosis, and emerging treatment options

Sleep apnea is an entity characterized by repetitive upper airway obstruction resulting in nocturnal hypoxia and sleep fragmentation. It is estimated that 2%-4% of the middle-aged population has sleep apnea with a predilection in men relative to women. Risk factors of sleep apnea include obesity, gender, age, menopause, familial factors, craniofacial abnormalities, and alcohol. Sleep apnea has been increasingly recognized as a major health burden associated with hypertension and increased risk of cardiovascular disease and death. Increased airway collapsibility and derangement in ventilatory control responses are the major pathological features of this disorder. Polysomnography (PSG) is the gold-standard method for diagnosis of sleep apnea and assessment of sleep apnea severity; however, portable sleep monitoring has a diagnostic role in the setting of high pretest probability sleep apnea in the absence of significant comorbidity. Positive pressure therapy is the mainstay therapy of sleep apnea. Other treatment modalities, such as upper airway surgery or oral appliances, may be used for the treatment of sleep apnea in select cases. In this review, we focus on describing the sleep apnea definition, risk factor profile, underlying pathophysiologic mechanisms, associated adverse consequences, diagnostic modalities, and treatment strategies.

Psychological variables as predictors of adherence to treatment by continuous positive airway pressure

STUDY OBJECTIVES

We examined whether psychological variables enable us to predict adherence to CPAP in order to construct a predictive model to identify patients at risk of abandoning treatment.

METHOD

One hundred and twenty-two Obstructive Sleep Apnoea (OSA) patients were studied before and one month after beginning CPAP treatment. All patients completed four psychological evaluation instruments before CPAP treatment: a health perception questionnaire (Nottingham Health Profile: NHP), a mental health rating scale (Hospital Anxiety and Depression Scale: HADS) and two disease-specific questionnaires that measure the patient's understanding of OSA and its treatment (Apnea Knowledge Test: AKT) and his attitudes to OSA and CPAP (Apnea Beliefs Scale: ABS).

RESULTS

Thirty percent of the participants were non-adherent at one month. Decision-tree analysis indicated that it was possible to correctly classify 85.7% of non-adherent patients using three baseline factors (Emotional reactions score [NHP], age, and total score on ABS). Logistic regression analyses confirmed these two psychological variables as independent predictors of adherence.

CONCLUSION

Assessing psychological well-being and subjective health status at onset of CPAP enables the identification of patients at risk of abandoning CPAP treatment. This subgroup could then be targeted early to receive supportive and educational measures to improve adherence rates.

Effect of Nasal Continuous Positive Airway Pressure Therapy on Health-related Quality of Life in Sleep Apnoea Patients Treated in the Routine Clinical Setting of a University Hospital

The effectiveness and cost-utility of nasal continuous positive airway pressure (nCPAP) treatment was evaluated in obstructive sleep apnoea syndrome (OSAS), using a 15D health-related quality of life (HRQoL) instrument in a routine clinical setting. In total, 78 OSAS patients (43 receiving nCPAP; 35 receiving lifestyle guidance) were included in the study. nCPAP treatment had a minor effect on the total HRQoL score; only the dimension of sleep improved in both groups. The mean ± SD number of quality-adjusted life years (QALYs) gained was 0.016 ± 2.34 in the nCPAP group and 0.386 ± 1.16 in the lifestyle guidance group. The mean cost per QALY gained was €73 375 for the nCPAP group and €845 for the lifestyle guidance group. The effect of nCPAP treatment on the HRQoL in a population of unselected OSAS patients was surprisingly small and the cost per QALY gained was high.

Health related quality of life in Greek patients with sleep apnea-hypopnea syndrome treated with continuous positive airway pressure

Sleep apnea-hypopnea syndrome (SAHS) causes serious symptoms and may induce patients' quality of life impairment. The aim of this study was to assess health related quality of life (HRQOL) in Greek patients with various severity SAHS before and after CPAP implementation in comparison with conservative therapy and Greek population normative data. In 180 patients (152 males, 28 females) with SAHS (apnea-hypopnea index, AHI 56 +/- 25.4/h), daytime sleepiness was assessed with the Epworth sleepiness scale (ESS) and measurements of health status were performed using the short form-36 health survey (SF-36) questionnaire and the General Health Questionnaire (GHQ-30). One hundred and thirty five patients underwent CPAP treatment and 45 were assigned to a conservative therapy. After 3 months the measurements were repeated in 105 patients under CPAP treatment and in 15 patients from the conservative group. HRQOL in all patients was lower than Greek normative data before any treatment. In patients with CPAP therapy the ESS decreased (p<0.01) and a significant improvement was observed in SF-36 dimensions (p<0.01). The improvement was more obvious in patients with severe SAHS (p<0.05) than in patients with moderate disease severity. In the majority of patients (60.9%), GHQ-30 score was high and it was negatively related to some SF-36 dimensions and positively to ESS. In patients under conservative therapy, no significant changes were observed in any measure. HRQOL in patients with SAHS at the time of diagnosis was low and reached general population levels in patients treated with CPAP. The improvement was greater in those with severe syndrome.

Evaluation of autoCPAP devices in home treatment of sleep apnea/hypopnea syndrome

BACKGROUND AND PURPOSE

Quality of life (QOL) and sleepiness for patients with sleep apnea/hypopnea syndrome (SAHS) might improve with continuous positive airway pressure devices working in auto-adjust mode (autoCPAP) by allowing pressure modulations following patient needs. Clinical comparisons between devices driven by different algorithms are needed.

METHODS

We compared the clinical effectiveness of fixed pressure CPAP and four different autoCPAP devices by assessing compliance and QOL (36-item short-form health survey [SF-36]). SAHS patients were randomly allocated to five groups. Polysomnography (PSG) was performed to titrate the effective pressure in the constant CPAP group and evaluate residual apnea/hypopnea index (AHI) under autoCPAP. Follow-up consisted of clinical visits at three and six months by homecare technicians who assessed compliance, symptom scores and SF-36 scores. A laboratory-based PSG using the same CPAP/autoCPAP device as at home was performed at six months.

RESULTS

Eighty-three patients (mean age 56+/-10 yrs) with mean body mass index (BMI) 30.8+/-5.3 kg/m(2) and severe SAHS (mean AHI: 52.3+/-17.8/h) were included. There were no differences in clinical symptoms or QOL scores, and similar clinical and PSG improvements were seen in all groups. CPAP use was >5 h per night, without any significant difference between groups.

CONCLUSIONS

AutoCPAP is equally as effective as fixed CPAP for long-term home treatment in severe SAHS patients.

The effect of one versus two nights of in-laboratory continuous positive airway pressure titration on continuous positive airway pressure compliance

OBJECTIVE

To investigate continuous positive airway pressure (CPAP) compliance after one versus two nights of CPAP titration.

METHOD

A chart review and a telephone questionnaire interview were conducted in 110 sleep apnea patients who received one or two nights of CPAP titration. Of these patients, 78 followed through with phone interview.

RESULTS

There was no difference in CPAP compliance between those who had one or two nights of CPAP titration. The titration pressures on the first and second nights were not significantly different. But there was significant improvement in sleep efficiency from the first to the second diagnostic night.

CONCLUSION

One versus two nights of CPAP titration did not affect CPAP compliance, but sleep efficiency improved on the second diagnostic night and an extra titration study may be necessary for some patients, especially those with only one diagnostic night.

Health-related quality of life in patients with sleep-related breathing disorders: relationship with nocturnal parameters, daytime symptoms and comorbid diseases

BACKGROUND

Sleep-related breathing disorders (SRBD) are frequently encountered health problems in the general population. Habitual snoring and obstructive sleep apnea/hypopnea syndrome (OSAHS) constitute most SRBD diagnoses. Although the decrease in quality of life is a well-known entity in SRBD patients, there is not enough data regarding the underlying pathophysiological mechanisms to explain this deterioration.

OBJECTIVES

The aim of this study was to investigate which parameters were affecting the quality of life in patients with SRBD.

METHODS

Medical Outcome Survey - Short Form 36 (SF-36) and Epworth Sleepiness Scale were used in 135 patients with SRBD (69 patients with OSAHS and 66 patients with habitual snoring), and Charlson comorbidity index was calculated. Acquired data were compared with leading symptoms and polysomnographic findings in these patients.

RESULTS

All SF-36 scores were significantly decreased in SRBD patients. However, there were no significant differences in the SF-36 scores of these patients. Also, no significant correlation was found between the severity of OSAHS and the SF-36 scores. Similarly, none of the polysomnographic parameters was found significantly correlated with SF-36 scores. In contrast, all SF-36 scores were influenced by body mass index, Epworth Sleepiness Scale score, mean nocturnal saturation and the presence of coexisting diseases.

CONCLUSIONS

According to the results of multiple variance analysis, we concluded that the quality of life depends on a number of collaborative factors such as obesity, mean nocturnal saturation, symptoms related to SRBD and the presence of comorbid diseases, rather than only on one independent parameter in the patients with SRBD.

A multicentre trial of education strategies at CPAP induction in the treatment of severe sleep apnoea–hypopnoea syndrome

BACKGROUND AND PURPOSE

Compliance with continuous positive airway pressure (CPAP) treatment in obstructive sleep apnoea syndrome (OSAS) may be difficult. Patient education is important but strategies and their outcomes are not clear.

PATIENTS AND METHODS

We studied the effects of four education strategies on compliance and quality of life changes with CPAP treatment in seven centres in the French ANTADIR homecare network. Patients received from prescribers either a simple oral explanation (SP) or an oral and written explanation (RP) of CPAP use. In addition, they received from homecare technicians either a single home visit (SH) at CPAP onset or repeated home visits at CPAP onset and at 1 week, 1 month and 3 months after (RH). Compliance and quality of life were evaluated at CPAP onset, and at 3, 6 and 12 months after initiation of treatment.

RESULTS

One hundred twelve patients with severe OSAS (mean age 58+/-11 year, apnoea-hypopnoea index 58+/-25/h) were allocated randomly to groups (SP+SH; SP+RH; RP+SH; RP+RH) with no initial differences. Quality of life, evaluated by the generic SF-36 questionnaire, improved in the combined emotional domains. Compliance was over 5h in all four education groups. These effects were sustained over 12 months and were not different between the four groups. We conclude that standard education strategies for CPAP induction in France are sufficient for good compliance and improved quality of life with CPAP. Education with reinforced input should be focussed on identified subgroups prone to problems.

A preliminary study of psychological factors affecting patients' acceptance of CPAP therapy for sleep apnoea syndrome

BACKGROUND

Many patients abandon continuous positive airway pressure (CPAP) treatment after initial acceptance. This may be for physical or psychological reasons.

METHODS

We have carried out semi-structured interviews, constructed from the Health Belief Model (HBM) with a convenience sample of patients who had recently abandoned CPAP treatment after at least 6 months of use. We explored their understanding and experiences of their OSA and of the CPAP therapy and their reasons for stopping treatment.

RESULTS

Nine patients were interviewed (age 32-70 years; 8 males). Four patients were not clear about the nature, severity, or consequences of sleep apnoea syndrome (SAS) and did not consider themselves to be ill. Three expected to be cured by the machine. Only one patient spoke of life-threatening risk. Eight of the nine patients had other health disorders. Seven stopped CPAP because of negative experiences, including problems with the mask and noise from the machine. Two patients felt 'liberated' on stopping treatment.

CONCLUSIONS

Studies at the initiation stage of CPAP treatment are needed in order to identify factors impeding acceptance, which can be addressed early. The Health Belief Model, which emphasises subjective health experience and patients' beliefs about treatment, may be a useful tool for such investigations.

Disorders of Sleep and Wake in Patients After Subarachnoid Hemorrhage

BACKGROUND AND PURPOSE

To determine the frequency and severity of disorders of sleep and wake and their relation to the quality of life (QoL) in patients who have survived an episode of subarachnoid hemorrhage (SAH).

METHODS

In a prospectively collected, consecutive series of 89 patients, 83 patients completed validated and frequently used questionnaires for the assessment of disorders of sleep and wake (SDL and Epworth Sleepiness Score) at least 1 year (range, 1 to 3.4 years) after the SAH. We used the modified Rankin scale for functional outcome and Short Form 36 (SF-36) to assess QoL. We related the occurrence of severe problems with sleep (insomnia or excessive daytime sleepiness score or both > or =3 on SDL) to functional outcome and to the QoL scores and compared the latter scores with data from a Dutch reference population. In a subset of 20 patients with severe problems with sleep, we performed polysomnographic and actigraphic studies at home during 48 hours.

RESULTS

Twenty eight (34%) patients had severe problems with sleep. Frequently reported problems are initiating (25%) or maintaining (31%) sleep, difficulty returning (28%) asleep, tiredness (31%), and excessive sleepiness during the day (6%). QoL was considerably reduced in patients with severe problems with sleep. During the sleep monitoring studies, severe sleep fragmentation, sleep apnea, restless legs syndrome/periodic limb movement disorder, or a combination of these disorders of sleep and wake occurred in 19 of 20 patients.

CONCLUSIONS

Many patients who have survived an episode of SAH have disorders of sleep and wake, which are related to the QoL.

Quality of life in sleep disorders

Quality of life is a major outcome variable in choosing and evaluating treatment alternatives for sleep disorders. However, the number of well validated and sufficiently responsive quality of life measures for use with this population is limited. The SF-36, Nottingham Health Profile (NHP) and Sickness Impact Profile (SIP) are the most frequently used generic measures. The Functional Outcomes of Sleep Questionnaire (FOSQ) and Sleep Apnoea Quality of Life Index (SAQLI) are useful as condition/disease specific measures. However there are not yet specific measures in common use for other sleep disorders. Results across the sleep disorders that have been studied, primarily sleep apnea, narcolepsy, restless legs and insomnia, have consistently shown poorer quality of life than population norms prior to treatment, particularly in those dimensions related to sleep, energy and fatigue. Before treatment scorespes typically are of similar magnitude to those found among individuals with other chronic diseases such as hypertension and chronic obstructive pulmonary disease. With treatment quality of life scores may or may not improve to the level of population norms, suggesting that currently available treatments may not fully reverse the effects of the common sleep disorders.

Quality of life in obstructive sleep apnea: a systematic review of the literature

OBJECTIVE

To review the literature on obstructive sleep apnea (OSA) and health-related quality of life (HRQOL).

BACKGROUND

OSA affects nearly one in four men and one in ten women aged 30-60 years in the United States. Health consequences of OSA can include neuropsychiatric and cardiovascular sequela that disrupt professional, family, and social life and negatively impact HRQOL.

METHODS

We conducted a comprehensive review of the literature on HRQOL and OSA, with special attention paid to instruments developed specifically for OSA.

RESULTS

Generic instruments used to study HRQOL and OSA include: Medical Outcomes Study Short Form-36, Nottingham Health Profile, Sickness Impact Profile, Functional Limitations Profile, EuroQol, and Munich Life Quality Dimension List. Specific instruments include: Calgary Sleep Apnea Quality of Life Instrument, Functional Outcomes of Sleep Questionnaire, OSA Patient Oriented Severity Index, the OSA-18, and Cohen's pediatric OSA surgery quality of life questionnaire.

CONCLUSIONS

OSA patients have impaired HRQOL when compared with healthy age- and gender-matched controls. Treatment with continuous positive airway pressure appears to improve HRQOL. Other treatment modalities have not been rigorously studied. In addition, more data are needed from preference-based measures that allow conversion to utility scores, which can be used to calculate quality-adjusted life years and cost-effectiveness ratios.

Neuropsychological impairment and quality of life in obstructive sleep apnea

Although clinical experience has suggested for more than two decades that OSA is associated with impairment of cognition, emotional state, and quality of life and that treatment with nasal CPAP produces significant improvements in these areas, sound empirical evidence to support this view, especially regarding treatment outcome, has been lacking. More recent investigations have begun to provide this support from randomized, adequately controlled studies. These assessments suggest that some degree of cognitive dysfunction is associated with OSA. The effects are most apparent in the severe cases, whereas results in mild cases are more equivocal. Reported impairments include global intellectual dysfunction and deficits in vigilance, alertness, concentration, short- and long-term memory, and executive and motor function. Considerable discrepancy exists across studies with respect to type and degree of dysfunction, however. Disturbances in general intellectual function and executive function show strongest correlations with measures of hypoxemia. Not unexpectedly, alterations in vigilance, alertness, and, to some extent, memory seem to correlate more with measures of sleep disruption. Although many inadequately controlled investigations have demonstrated reversibility of most or all of these deficits with effective treatment, more recent placebo-controlled studies have raised doubts regarding whether the observed changes are truly a function of treatment. This issue requires further systematic exploration with adequate controls and step-wise analysis of treatment duration effects. A similar set of considerations exists with respect to the relationship between psychological disturbance, primarily depression, and OSA. Although several studies suggest significant depression in these patients, the results are mixed. Placebo-controlled treatment trials fail to demonstrate consistently a difference in mood improvement between active treatment groups and controls, although several methodologic considerations suggest that these results should be interpreted with caution. Numerous investigations leave little doubt about the issue of quality of life impairment among persons with OSA. Further characterization of impairment, particularly in areas specific to this population, will provide clearer understanding of the problem. Preliminary investigations of treatment response in controlled studies indicate significantly greater improvement of quality of life in response to CPAP. Although patients with OSA commonly report disturbances in cognitive and psychological function and general quality of life, the increased rates of obesity, hypertension, diabetes, cardiovascular disease, medication use, and related psychosocial complications present a host of potential etiologies that might explain the impairments noted. There can be little doubt that these covariants do, in some cases, contribute to neuropsychological dysfunctions. It is essential that future studies continue to define those disturbances that are specific to OSA, the relationship between levels of severity and impairment, the role of treatment in reversing these dysfunctions, and the correlation between test results and significant day-to-day social and occupational functional impairment.

A randomized, controlled trial of 1 week of continuous positive airway pressure treatment on quality of life

BACKGROUND

This study examines the effect of continuous positive airway pressure (CPAP) treatment on quality of life (QOL)in patients with obstructive sleep apnea.

METHODS

Thirty-nine patients with sleep apnea were studied. Health-related quality of life was measured (HRQL) with the use of the Medical Outcomes Survey (MOS) instrument, before and after patients were randomized to receive either 1 week of CPAP or placebo-CPAP (CPAP administered at ineffective pressure).

RESULTS

CPAP was not found to have a specific effect on QOL as compared with placebo-CPAP. However, several aspects of HRQL improved in both groups over time in this study. Time effects were found in the following subscales of the MOS: satisfaction with physical functioning; effects of pain; pain severity; cognitive functioning; mental health index I; psychological well-being I; depression/behavioral-emotional control; anxiety I; psychological distress I; positive affect II; mental health index II; psychological distress II; anxiety II; psychological well-being II; mental health index III; role limitations due to emotional problems; and physical/physiologic functioning.

CONCLUSIONS

CPAP treatment does appear to improve several aspects of HRQL. However, this improvement may reflect a nonspecific response (ie, placebo) because comparable improvements were observed in both the active treatment group and the placebo treatment group. Additional study with placebo-CPAP designs is warranted.

[Suitability of the Munich List of Quality of Life Dimensions (MLDL) for use in logopedic therapy research]

Public health policy increasingly focuses on criteria of cost and cost-effectiveness for health care financing. However, tools for assessing the effects of logopedic therapy are largely missing. This study investigated the suitability of the Munich List of Quality-of-Life-Dimensions (MLDL) for use with patients with dysphonia. Twenty-five adults with voice disorders were administered the MLDL at the beginning and at the end of therapy (about 20 sessions). Results were that, although most patients expressed high satisfaction with the therapy received, MLDL scores did not reflect this. Only 2 out of 19 items of the scale indicated a significant improvement in the quality of life after therapy ("ability to relax", p < 0.05, and "satisfaction with the treatment of the disorder", p < 0.01). The MLDL is not sensitive enough to detect all effects of logopedic therapy. The development of specific scales for the detection of effects of logopedic intervention is discussed.

Can continuous positive airway pressure therapy improve the general health status of patients with obstructive sleep apnea?: a clinical effectiveness study

STUDY OBJECTIVES

To determine the short-term and long-term impacts of continuous positive airway pressure (CPAP) therapy on health-related quality of life (HRQL) in patients with obstructive sleep apnea (OSA).

DESIGN

Prospective longitudinal cohort study.

SETTING

University sleep disorders center.

PATIENTS

Three hundred sixty-five patients with an apnea-hypopnea index (AHI) > or = 20 per hour of sleep and 358 patients with an AHI of < 20.

INTERVENTIONS

All patients with AHIs > or = 20 received CPAP therapy; those with AHIs < 20 did not. The HRQL of all study participants was measured using the 36-item medical outcomes study short form (SF-36) questionnaire at baseline and then at 3 and 12 months of follow-up.

RESULTS

Although the SF-36 scores were similar at baseline, after 3 months of therapy, the CPAP group had higher adjusted emotional summary scores than did those who did not receive CPAP therapy (score increase, 1.72; 95% confidence interval [CI], 0.08 to 3.37). These improvements were maintained for 12 months. The gains in the SF-36 scores were most striking in the vitality domain (score increase, 10.52; 95% CI, 7.04 to 14.00 U increment). The severe OSA group (ie, AHIs > or = 40) experienced the largest benefit. Their adjusted vitality scores were 12.3 U higher (95% CI, 8.0 to 16.6) than those persons without OSA (ie, AHIs < 5).

CONCLUSIONS

CPAP therapy was associated with marked short-term and long-term improvements in the vitality of patients with moderate-to-severe OSA in the community. These findings suggest that CPAP therapy is effective in improving the long-term HRQL of patients with OSA.

Knowledge of sleep apnea in a sample grouping of primary care physicians

The purpose of this pilot study was to examine four groups of primary care physicians' knowledge of sleep apnea.

METHODS

Using a 36-item questionnaire, we investigated how cognizant primary care physicians in Ontario, Canada, were of sleep apnea and its different symptoms. The questions covered incidence, diagnosis, treatment, and medical and social ramifications of sleep apnea. Sleep apnea surveys were administered to small groups of primary care physicians attending educational conferences or were distributed by mail to physicians who had previously referred patients to the sleep clinic.

RESULTS

A total of 151 physicians responded to the survey. An overall average score of 69% was obtained on the questionnaire.

CONCLUSIONS

This score suggests that the physicians sampled in this pilot study are relatively under-informed about the clinical features and medical and social ramifications associated with sleep apnea.

Effect of nasal continuous positive airway pressure on neuropsychological function in sleep apnea-hypopnea syndrome. A randomized, placebo-controlled trial

A placebo-controlled, partial cross-over, double-blind, randomized study was performed with 46 adults with sleep apnea-hypopnea syndrome (SAHS) to determine the effect of therapeutic and subtherapeutic (0-1 cm H(2)O) nasal continuous positive airway pressure (CPAP) treatment on polysomnographic and neuropsychological testing. The following neuropsychological tests were administered: Geriatric Depression Scale, Trail Making A and B, Digit Span Test Forward and Backward, Epworth Sleepiness Scale, SteerClear, Digit Symbol, Controlled Oral Word Association, and Complex Figure Recall. Compared with results without CPAP, subtherapeutic CPAP did not affect any measured polysomnographic parameter. Comparison of neuropsychological test results obtained between the initial periods of effective treatment (Group 1, 16.1 d; Group 2, 19.6 d; p = NS) in all subjects showed significant improvements in Digit Symbol, Digit Span Backward, and Complex Figure tests. However, there were no group differences in changes in test results during the period when one group was on effective CPAP and the other on ineffective CPAP (Group 1, 16.1 d; Group 2, 13.9 d; p = NS). The results indicate the feasibility and importance of using ineffective CPAP as a placebo treatment and the importance of including a placebo control in studies evaluating the effect of treatment on neuropsychological function in SAHS.

Optimal continuous positive airway pressure for the treatment of obstructive sleep apnea/hypopnea

The obstructive sleep apnea/hypopnea syndrome (OSA/H) is characterised by repetitive obstruction of the upper airway during sleep. The consequences of OSA/H include excessive daytime sleepiness, reduced perceived health quality and an increased risk of driving accidents. There is evidence that treatment with nasal continuous positive airway pressure (CPAP) is effective in eliminating these consequences. In addition, OSA/H may also be associated with hypertension and an increased risk of vascular disease, and although there is no clear evidence in this regard, CPAP may be effective alleviating these consequences as well. Nasal CPAP is considered the treatment of choice for clinically significant OSA/H. The optimal CPAP prescription is that which is most effective in eliminating the adverse consequences of OSA/H. Patients should be initially treated with standard CPAP. For those in whom standard CPAP is unsuccessful or intolerable bi-level or self-adjusting modes may be attempted. The nasal CPAP pressure level can be titrated to eliminate apnea, hypopnea, snoring, respiratory arousal and inspiratory flow limitation as a means of predicting successful long-term therapy. The reliability of these physiologic parameters in predicting the optimal long-term CPAP pressure is eroded by the tendency of CPAP pressure-level requirement to decrease with chronic CPAP use, and by other factors that may increase the CPAP pressure requirement. The split-night polysomnogram and unattended auto-CPAP titration have been proposed as efficient means of determining the optimal CPAP pressure, but for patients with subtle OSA/H, underlying cardiopulmonary disease or other forms of sleep-disordered breathing a full-night polysomnogram may be required. The CPAP prescription must include a comfortable well-fitting interface. When CPAP is prescribed it is essential that the patient undergo clinical re-evaluation to ensure that treatment goals are being met.

CLINICAL REVIEW ARTICLE: Epidemiology of sleep-related obstructive breathing

The diagnosis of obstructive sleep apnoea syndrome (OSAS) and upper airway resistance syndrome (UARS) is based both on a combination of laboratory findings from whole-night sleep recordings and daytime symptoms. Due to the recent interest in breathing disturbances during sleep many prevalence studies have been performed within this field. There are, however, methodological difficulties in characterizing these syndromes in large populations; many of the studies have therefore been unable to present an overview of the complete syndromes but rather have focused on specific characteristics. In epidemiological research snoring and/or daytime sleepiness have often been used as markers of OSAS, while other studies have looked only on the respiratory disturbances or oxygen desaturation. Studies on the prevalence of OSAS based on polysomnography are reviewed here, as well as investigations where associated factors such as cardiovascular diseases and mortality were analysed. The interrelationships between snoring, daytime symptoms and laboratory findings are discussed. Gender, age, obesity, smoking, alcohol and ethnicity are all factors that influence the prevalence of OSAS. The data on associations between OSAS and cardiovascular disease or mortality are sometimes unrelated. Much of the discrepancy between different studies can be explained by the methodological difficulties connected with the definition of OSAS and also by the fact that the association between sleep-disordered breathing and cardiovascular outcome seems to be age-dependent.